Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Headlines
    3. >Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug
    Headlines

    Royalty Pharma to Pay up to $950 Million for Royalties From Amgen's Lung Cancer Drug

    Published by Global Banking & Finance Review®

    Posted on August 25, 2025

    2 min read

    Last updated: January 22, 2026

    Add as preferred source on Google
    Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:portfoliosinvestmentfinancial communityequitydebt instruments

    Quick Summary

    Royalty Pharma will pay up to $950M for royalties from Amgen's lung cancer drug, Imdelltra, enhancing its oncology portfolio.

    Royalty Pharma Acquires Up to $950 Million in Amgen Lung Cancer Royalties

    Royalty Pharma's Strategic Acquisition

    (Reuters) -Royalty Pharma has agreed to buy a royalty interest in Amgen's drug for small cell lung cancer from BeOne Medicines for up to $950 million, it said on Monday.

    Details of the Deal

    The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, Imdelltra, which won U.S. approval last year for patients with extensive-stage small cell lung cancer who have failed chemotherapy.

    Impact on Royalty Pharma's Portfolio

    Royalty Pharma will pay $885 million upfront, while Chinese drug developer BeOne will retain an option to sell an additional portion for up to $65 million within the next 12 months. BeOne, formerly known as BeiGene, will keep commercial rights to the therapy in China.

    Sales Projections for Imdelltra

    The royalties from the drug are expected to last until between 2038 and 2041.

    This agreement strengthens Royalty Pharma's portfolio of oncology-related royalty streams, the company said. In 2022, it had bought royalty interests in Roche’s lung cancer drug Gavreto for up to $340 million.

    Amgen's Imdelltra reduced the risk of death by 40% compared with chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data in June from a late-stage trial.

    Imdelltra sales reached $215 million in the first half of the year and are projected to exceed $2.8 billion by 2035 based on analyst consensus, Royalty Pharma said.

    (Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

    Table of Contents

    • Royalty Pharma's Strategic Acquisition
    • Details of the Deal
    • Impact on Royalty Pharma's Portfolio
    • Sales Projections for Imdelltra

    Key Takeaways

    • •Royalty Pharma acquires Amgen's lung cancer drug royalties.
    • •Deal worth up to $950 million with BeOne Medicines.
    • •Royalty Pharma strengthens oncology portfolio.
    • •Imdelltra sales projected to exceed $2.8 billion by 2035.
    • •Amgen's drug reduces death risk by 40% in trials.

    Frequently Asked Questions about Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug

    1What is a royalty?

    A royalty is a payment made to the owner of a property, such as a patent or copyright, for the right to use that property. In finance, it often refers to payments made for the use of intellectual property.

    2What is a portfolio in finance?

    A portfolio is a collection of financial assets such as stocks, bonds, and other investments held by an individual or institution. It is managed to achieve specific investment goals.

    3What is equity?

    Equity represents ownership in a company, typically in the form of shares. Shareholders benefit from the company's profits and may have voting rights in company decisions.

    4What are debt instruments?

    Debt instruments are financial assets that represent a loan made by an investor to a borrower. They include bonds, notes, and mortgages, and typically involve interest payments.

    5What is investment?

    Investment is the act of allocating resources, usually money, in order to generate income or profit. It can involve purchasing assets like stocks, bonds, or real estate.

    More from Headlines

    Explore more articles in the Headlines category

    Image for In Lebanon, paramedics mourn their own killed in Israeli strike
    In Lebanon, Paramedics Mourn Their Own Killed in Israeli Strike
    Image for Italy tourism minister resigns, obeying PM Meloni
    Italy Tourism Minister Resigns, Obeying PM Meloni
    Image for Swiss prosecutors not involved with Paris probe at bank Edmond de Rothschild
    Swiss Prosecutors Not Involved With Paris Probe at Bank Edmond De Rothschild
    Image for Lost remains of French musketeer d'Artagnan may have been found in Dutch church
    Lost Remains of French Musketeer d'Artagnan May Have Been Found in Dutch Church
    Image for Doctors in England plan six-day strike after government pay offer rejected
    Doctors in England Plan Six-Day Strike After Government Pay Offer Rejected
    Image for Soccer-Man sentenced for racist abuse of England defender Carter
    Soccer-Man Sentenced for Racist Abuse of England Defender Carter
    Image for Netanyahu seeks to avoid snap vote as Iran war gives no boost in polls
    Netanyahu Seeks to Avoid Snap Vote as Iran War Gives No Boost in Polls
    Image for Cyprus has opened discussion with UK over its bases, president says
    Cyprus Has Opened Discussion With UK Over Its Bases, President Says
    Image for Once inspired by Orban, Hungary's Peter Magyar now leads the charge to unseat him
    Once Inspired by Orban, Hungary's Peter Magyar Now Leads the Charge to Unseat Him
    Image for German foreign minister hopes Iran peace talks given chance to work
    German Foreign Minister Hopes Iran Peace Talks Given Chance to Work
    Image for Factbox-What's at stake in Hungary's parliamentary election?
    Factbox-What's at Stake in Hungary's Parliamentary Election?
    Image for Hezbollah chief rejects talks with Israel under fire, vows fighters will continue 'without limits'
    Hezbollah Chief Rejects Talks With Israel Under Fire, Vows Fighters Will Continue 'without Limits'
    View All Headlines Posts
    Previous Headlines PostSweden Agrees to Sell Four Saab Gripen Fighter Jets to Thailand
    Next Headlines PostThree Dead in Helicopter Crash During Flying Lesson on UK's Isle of Wight